Technical Data
S9500-21A
Synuclein, alpha, CT (SNCA, 127750, P37840, MGC110988, NACP, PARK1, PARK4, non-A beta Component of AD Amyloid, NACP, Parkinson Disease Familial 1, PD1)
|
Technical Data |
|
S9500-21A |
Synuclein, alpha, CT (SNCA, 127750, P37840, MGC110988, NACP, PARK1, PARK4, non-A beta Component of AD Amyloid, NACP, Parkinson Disease Familial 1, PD1) |
|
|
Description: Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly. An early step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43aa peptides (beta amyloid1-40, 1-42, and 1-43). Polymerization of b-amyloid (Ab) and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. Ab deposits have also been found to contain 2 additional proteins termed a-synuclein and b-synuclein. The 140aa a-synuclein is identical with non-Ab component (NACP) of AD. The 134aa b-synuclein is homologous to 14kD bovine phosphoneuroprotein 14. Mutations in a-synuclein gene causing a replacement of alanine with a threonine has the potential to cause the protein to misfold. Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Recommended Dilution: ELISA: 1:10,000-1:100,000 using 50-100ng of control peptide/well Western Blot: 1-10ug/ml. Optimal dilutions to be determined by the researcher. Control Peptide: S9500-21P Storage and Stability: May be stored at 4°C for short-term only. For long-term storage, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. |
|
|||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||